Citius Pharmaceuticals (CTXR) Competitors $1.49 -0.14 (-8.59%) Closing price 04:00 PM EasternExtended Trading$1.52 +0.03 (+2.08%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. INCR, PMVP, VTGN, GNTA, RPTX, IRD, ANEB, IKNA, KLTO, and CNTXShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include InterCure (INCR), PMV Pharmaceuticals (PMVP), VistaGen Therapeutics (VTGN), Genenta Science (GNTA), Repare Therapeutics (RPTX), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Ikena Oncology (IKNA), Klotho Neurosciences (KLTO), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors InterCure PMV Pharmaceuticals VistaGen Therapeutics Genenta Science Repare Therapeutics Opus Genetics Anebulo Pharmaceuticals Ikena Oncology Klotho Neurosciences Context Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends. Do analysts prefer CTXR or INCR? Citius Pharmaceuticals presently has a consensus price target of $53.00, suggesting a potential upside of 3,457.05%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, CTXR or INCR? Citius Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Do institutionals & insiders hold more shares of CTXR or INCR? 16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, CTXR or INCR? InterCure has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/AInterCure$64.55MN/A-$18.32MN/AN/A Is CTXR or INCR more profitable? InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -58.63% -37.67% InterCure N/A N/A N/A Does the media refer more to CTXR or INCR? In the previous week, Citius Pharmaceuticals had 2 more articles in the media than InterCure. MarketBeat recorded 5 mentions for Citius Pharmaceuticals and 3 mentions for InterCure. InterCure's average media sentiment score of 1.07 beat Citius Pharmaceuticals' score of 0.37 indicating that InterCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InterCure 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCitius Pharmaceuticals beats InterCure on 7 of the 12 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.33M$2.42B$5.52B$9.32BDividend YieldN/A1.79%4.25%4.05%P/E RatioN/A9.1828.1519.68Price / SalesN/A736.97438.32100.43Price / CashN/A160.6835.5357.53Price / Book0.154.698.235.67Net Income-$39.14M$30.99M$3.23B$257.51M7 Day Performance-15.82%0.60%-0.01%0.52%1 Month Performance88.58%7.93%5.61%8.84%1 Year Performance-92.99%-5.48%26.52%14.18% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals3.0166 of 5 stars$1.49-8.6%$53.00+3,457.0%-91.5%$17.33MN/A0.0020News CoverageINCRInterCure0.6726 of 5 stars$1.55flatN/A-37.4%$70.63M$238.85M0.00350News CoveragePositive NewsPMVPPMV Pharmaceuticals3.1554 of 5 stars$1.35+7.1%$5.50+307.4%-18.4%$70.13MN/A-1.1450Positive NewsHigh Trading VolumeVTGNVistaGen Therapeutics0.719 of 5 stars$2.38flatN/A-42.5%$69.40M$490K-1.4340News CoveragePositive NewsGNTAGenenta Science2.6014 of 5 stars$3.78-4.5%$25.00+561.4%+10.0%$69.14MN/A0.007Positive NewsGap DownRPTXRepare Therapeutics3.0613 of 5 stars$1.57+4.7%$4.50+186.6%-60.3%$67.34M$53.48M-0.52180News CoveragePositive NewsGap UpIRDOpus Genetics1.8458 of 5 stars$1.11-1.8%$7.33+560.7%N/A$66.22M$10.99M-0.5314ANEBAnebulo Pharmaceuticals2.715 of 5 stars$1.61-3.0%$5.50+241.6%-35.1%$66.15MN/A-6.194Positive NewsGap UpIKNAIkena Oncology2.7667 of 5 stars$1.37-0.7%$3.00+119.0%-16.5%$66.11MN/A-1.5970News CoverageGap DownHigh Trading VolumeKLTOKlotho NeurosciencesN/A$1.25-3.8%N/AN/A$65.88MN/A-3.47N/ANews CoverageCNTXContext Therapeutics3.3246 of 5 stars$0.73+9.3%$5.50+651.2%-66.6%$65.68MN/A-2.367Positive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies INCR Competitors PMVP Competitors VTGN Competitors GNTA Competitors RPTX Competitors IRD Competitors ANEB Competitors IKNA Competitors KLTO Competitors CNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
